BCG strain S4-Jena: An early BCG strain is capable to reduce the proliferation of bladder cancer cells by induction of apoptosis

BACKGROUND: Intravesical immunotherapy with Mycobacterium bovis bacillus Calmette-Guérin has been established as the most effective adjuvant treatment for high risk non-muscle-invasive bladder cancer (NMIBC). We investigated the differences between the S4-Jena BCG strain and commercially available B...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwarzer, Katja, Foerster, Martin, Steiner, Thomas, Hermann, Inge-Marie, Straube, Eberhard
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2908063/
https://www.ncbi.nlm.nih.gov/pubmed/20587032
http://dx.doi.org/10.1186/1475-2867-10-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2908063/
https://www.ncbi.nlm.nih.gov/pubmed/20587032
http://dx.doi.org/10.1186/1475-2867-10-21

Ejemplares similares